NVTA: Invitae Corporation - Summary | Jitta

Invitae Corporation

NYSE:NVTA

Price
$17.64
Loss Chance
56.1%
1.73JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
184 / 555
552 / 1,123
3,711 / 4,767
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (38)
Recent Business Performance (31)
Financial Strength (40)
Return to Shareholders (0)
Competitive Advantage (44)
Jitta Signs
SG&A to SalesDecreasing
Cash Conversion CycleLess than 60 days
Revenue and EarningEarning loss detected in 2020
Operating MarginDeclined
Recent Business PerformanceEarning decline 3.87% in the last year
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.73
100.00%
1.31
126.53%
2.14
250.13%
Biotechnology
6.99
49.52%
2.57
57.30%
5.99
42.54%
COMPANY DESCRIPTION
Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. It has a collaboration with Pacific Biosciences of California, Inc. to develop a production-scale high-throughput HiFi sequencing platform. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.